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Since the original observations of Coley 
(1893),  and  the  subsequent  work  of 
Schreiber et al. (2011), it has been evi-
dent that the immune system is capable 
of detecting neoplastic transformation 
and eradicating spontaneous and ex-
perimentally induced tumors. However, 
despite this inherent ability, tumors es-
cape  immune  destruction  and  cancer 
still remains a major cause of death. It is 
well  known  that  cells  of  the  immune   
system  can  play  both  protective  and   
tumor-promoting roles during neoplastic 
transformation. Tumors undergo a pro-
cess known as immunoediting, result-
ing in the selection of a tumor that has 
established either a favorable microen-
vironment that facilitates its growth or 
an immunosuppressive environment that 
enables it to avoid immune destruction 
(Schreiber  et  al.,  2011).  In  this  issue, 
Molon et. al. describe a novel mecha-
nism of tumor immune escape involv-
ing  the  extracellular  modification  of 
the chemokine CCL2 within the tumor 
microenvironment,  rendering  it  un-
detectable by circulating lymphocytes. In 
this  minireview,  we  discuss  the  results   
of this paper and its significance in the 
context of our current understanding of 
the trafficking of antitumor T cells and 
tumor-induced immune suppression.
T cell infiltration correlates  
with prognosis
The  importance  of  tumor-infiltrating 
lymphocytes  (TILs)  is  highlighted  by 
their prognostic value in human cancer. 
Using genetic and histological analysis 
of a large cohort of colorectal cancer   
patient  biopsies,  Galon  et  al.  (2006) 
showed that both the type and location 
of  immune  cell  infiltrate  predicts  im-
proved patient survival. Specifically, pa-
tients whose tumor centers or invasive 
margins  were  highly  infiltrated  with   
T cells had the best predicted survival. 
In contrast, patients with stage I tumors 
containing few or no infiltrating T cells 
had a prognosis similar to metastatic stage 
IV patients, even though they origi-
nally presented with minimally inva-
sive disease (Galon et al., 2006). Many 
studies examining other cancers reached 
similar conclusions; consequently, a more 
defined picture has now developed in 
which immune infiltrates correlate with 
improved prognosis or protumorigenic 
potential. Each infiltrating immune cell 
type responds differentially to various 
anticancer treatments (Quezada et al., 
2011).  Therefore, a positive balance of anti-
tumor effector cells (M1 macrophages, 
CD8
+ T cells, and T helper type 1 cells) 
versus  tumor-promoting  suppressive 
cells (M2 macrophages, myeloid derived 
suppressor cells [MDSCs], and regula-
tory T cells [T reg cells]) in the tumor 
predicts  not  only  prognosis  but  also   
the therapeutic impact of chemotherapy 
and  immunotherapy  (Fridman  et  al., 
2011; Quezada et al., 2011). Identifying 
the mechanisms that prevent infiltration 
of antitumor effector cells is therefore 
of the utmost importance in optimizing 
therapeutic benefit.
Keeping the T cells out
After the initial priming of T cells in 
tumor-draining lymph nodes, success-
ful  trafficking  of  effector  cells  to  the   
tumor becomes the next goal for effec-
tive tumor immunity. Recent studies 
have  demonstrated  that  the  tumor 
vasculature itself, as a result of activa-
tion state or organization, can prevent   
T cell infiltration. Through the analysis 
of  gene  expression  profiles  of  tumor 
endothelium from human ovarian can-
cers, Buckanovich et al. (2008) discov-
ered the association of endothelin B 
receptor (ETBR) expression with the   
absence of TILs. Moreover, the ligand 
of ETBR, endothelin-1, is expressed   
by  ovarian  tumors  in  vivo  (Bagnato   
et al., 2005). When activated by ligand 
binding, ETBR causes up-regulation of 
nitric oxide (NO) synthases, leading to 
NO release from the vascular endo-
thelium (Tsukahara et al., 1994). NO 
in turn reduces both the expression of 
ICAM-1 and ICAM-1 clustering, pre-
venting T cell adhesion to the endo-
thelium  (Buckanovich  et  al.,  2008). 
Blocking  ETBR  with  an  antagonist 
peptide  prevented  the  modulation  of 
ICAM-1  and  resulted  in  increased   
T  cell  vasculature  adhesion  in  vitro 
(Buckanovich et al., 2008). Importantly, 
combining ETBR blockade with vaccine 
strategies or adoptive T cell therapy 
(ATC)  in  ovarian  ID8  and  HPV- 
expressing TC-1 tumor models enhanced 
Tumors exploit many strategies to evade T cell–mediated destruction. For 
example, tumors can prevent T cell infiltration by modifying gene expression 
in the endothelial cells and pericytes that form their vasculature. New work 
showing that the T cell–attracting chemokine CCL2 can be posttranslationally 
modified in the tumor microenvironment adds another mechanism to the 
already formidable arsenal of immunoevasion tactics used by solid tumors.
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have shown that not only do T cells con-
gregate in the periphery of the tumor,   
but in examples of ATC therapy, T cells 
must first kill tumor cells in the periph-
ery before working their way into the   
tumor itself (Boissonnas et al., 2007; Breart 
et  al.,  2008).  Using  this  same  model, 
Molon et al. (2011) showed that these 
tumors contained a significant amount 
of n-CCL2, which could explain the dis-
tribution and migration phenotype of TIL 
previously described for EG.7 tumors.
Putting T cells back on track
As mentioned earlier, the normalization 
of vasculature in Rgs5
/ mice or the 
blocking ETBR with antagonist peptides 
restored  T  cell  tumor  trafficking  and 
enhanced  the  therapeutic  benefit  of 
ATC therapy. In prior research, De Santo 
et al. (2005) showed that blocking pro-
duction of RNS with nitroaspirin pre-
vented the generation of n-Tyr inside 
tumors, leading to improved antitumor 
immunotherapy  with  vaccines.  In  the 
current study, nitroaspirin was not found 
to  be  an  effective  adjuvant  for  ATC 
therapy; Molon et al. (2011) therefore 
developed a new compound (AT38) that 
efficiently  blocked  the  production  of 
peroxynitrite. AT38 reduced the gen-
eration of n-Tyr and prevented nitro-
tyrosinylation  of  CCL2  in  TRAMP, 
C26GM, and EG.7 tumors. This treat-
ment reversed the block in T cell traffick-
ing and enabled adoptively transferred 
OT-1 TILs  to  migrate  into  the  core   
of EG.7 tumors leading to significantly 
enhanced tumor rejection and long-
term  protection  in  both  EG.7  and 
MCA-203  fibrosarcoma  models.  Be-
cause AT38 was unable to improve T cell 
infiltration when tumors were grown in 
Ccr2
/ mice, and because the effects of 
AT38 could be mimicked by the direct 
intratumoral  injection  of  unmodified 
CCL2 in wild-type mice, the effects of 
AT38 were likely directly related to the 
unmasking of CCL2.
Getting there may not always  
be the problem
The extent to which chemokine nitro-
tyrosinylation  and  subsequent  mask-
ing of TIL chemoattractant signals plays   
a role in other tumors remains to be   
peroxynitrite, whose rapidly arising break-
down product, the radical NO2, is a   
potent  nitrosylating  agent,  leading  to   
nitrotyrosinylation of proteins inside the 
tumor  microenvironment  (Bronte  and 
Zanovello, 2005; Nathan and Ding, 2010). 
The direct nitrotyrosinylation of impor-
tant signaling proteins in the T cell re-
ceptor (TCR) cascade is believed to block 
TCR  signaling  in  TILs  (Bronte  and   
Zanovello, 2005; Nagaraj et al., 2010). 
However,  while  investigating  the  pat-
tern of nitrotyrosine (n-Tyr) in human 
colorectal tumors, Molon et al. (2011) 
found an inverse distribution of n-Tyr 
and TILs. Staining for n-Tyr was observed 
mainly within the tumor core, whereas 
T cells accumulated in the periphery of 
the tumor. Given the considerable pro-
duction of n-Tyr inside various tumors, 
they  hypothesized  that  other  proteins 
such as the chemokine CCL2, an impor-
tant chemoattractant for TIL, could also 
be  nitrotyrosinalated.  After  developing 
an  antibody  that  could  distinguish  be-
tween nitrotyrosinalated CCL2 (n-CCL2) 
and  unmodified  CCL2,  Molon  et  al. 
(2011) demonstrated that n-CCL2 was 
present in human prostate and colon 
carcinomas.  The  significance  of  intra-
tumoral n-CCL2 was highlighted by ex-
periments  showing  that  neither  human   
nor mouse T cells were able to migrate 
toward  n-CCL2.  Conversely,  myeloid 
cells, which express higher levels of the 
CCL2 receptor (CCR2), were still able 
to detect and migrate toward n-CCL2. 
This is an important finding, as it is be-
lieved that immature myeloid cells, also 
known as MDSCs, are responsible for 
producing the intratumoral RNS that 
could lead to the production of n-CCL2. 
In support of this concept, we have re-
cently found that ablation of CCR2-
expressing myeloid cells directly enhances 
activated T cell entry into the tumor site, 
implying a critical role for CCR2
+ my-
eloid cells in limiting T cell entry into 
the tumor (unpublished data).
Previously, imaging studies of mouse 
EG.7  thymomas  undergoing  rejection 
have  demonstrated  that  intratumoral   
T cells engage in a random walk pattern, 
suggesting that they lack a specific chemo-
attractant signal to direct intratumor mi-
gration (Mrass et al., 2006). Further studies   
their therapeutic benefit, leading to de-
layed tumor growth through increased 
T cell infiltration.
Although  the  previous  example 
demonstrates how ovarian tumors can 
modulate the endothelial barrier through 
tumor-derived factors, the inherently dis-
organized  and  leaky  tumor  vasculature   
itself can also act as a major barrier to   
T cell infiltration. Investigating markers 
of  pathological  angiogenesis,  Berger   
et al. (2005) found that regulator of   
G-protein signaling-5 (RGS-5) was over-
expressed in pericytes of tumor neovas-
culature.  Normally,  early  tumors  in  the 
RIP1-Tag5 model of pancreatic islet cell 
cancer are characterized by  a  disorga-
nized and leaky vasculature that creates 
a hypoxic environment devoid of TILs. 
RGS5-expressing  pericytes  displaying 
an immature phenotype were found to 
preferentially  associate  with  this  highly 
angiogenic neovasculature (Manzur et al., 
2009).  Deletion  of  RGS-5  in  RIP1-
Tag5 mice resulted in pericyte matura-
tion  and  normalization  of  vasculature 
inside  the  tumor,  thereby  removing   
the  barrier  to  infiltrating  lymphocytes 
(Hamzah et al., 2008). ATC therapy with 
tumor-specific T cells or vaccination with 
tumor antigens substantially increased the 
survival  of  tumor-bearing  RIP1-Tag5 
Rgs5
/ mice, but had no effect in RIP1-
Tag5 Rgs5
+/+ mice.
Modifying the directions
Although the aforementioned examples 
show how trans-migration through the 
vascular endothelium into the tumor can 
represent a formidable barrier to tumor 
immunity, there are many cases where   
T cells are recruited to the tumor, yet 
remain  in  its  periphery  (Galon  et  al., 
2006; Mrass et al., 2006; Boissonnas et al., 
2007).  Determining  the  cause  of  this 
phenotype is the focus of the study by 
Molon  et  al.  (2011).  Previous  studies 
from the same group documented that 
reactive nitrogen species (RNS) are pro-
duced  inside  various  tumors  through 
metabolism  of  l-arginine  by  arginase 
and NO synthase (Bronte et al., 2005;   
De Santo et al., 2005). Arginase lowers 
l-arginine levels to the point that iNOS 
makes a mixture of NO and O2-. These 
react with each other to form the RNS JEM Vol. 208, No. 10 1939
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enhancement of both ATC and endog-
enous antitumor T cell responses. How-
ever, as noted in this study, commercial 
reagents are unable to detect n-CCL2, 
so  its  current  involvement  in  human 
cancer  and  preclinical  tumor  models 
may not yet be fully appreciated. Bar-
riers to T cell tumor infiltration, such   
as chemokine nitrosylation, should be   
considered another mechanism of tumor- 
induced immunosuppression. The com-
bination  of  current  immunotherapies 
with inhibition of n-CCL2 is a prom-
ising  venue  and  could  lead  to  better 
outcomes for cancer patients.
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Conclusion
Recent  advances  in  immune  check-
point blockade and ATC have brought 
therapeutic  options  to  patients  with   
advanced cancers where there had pre-
viously been none (Hodi et al., 2010; 
Robert et al., 2011; Rosenberg et al., 
2011). Yet, these successes are still lim-
ited to a subset of patients. Thus, fur-
ther  investigation  of  the  underlying 
causes  of  tumor  immune  escape  is 
needed  to  extend  clinical  benefit  to 
more patients. Modification of chemo-
kines by nitrosylation represents a signifi-
cant  new  paradigm  in  tumor-induced 
immune suppression (Fig. 1). Most im-
portantly, Molon et al. (2011) demon-
strate that this adverse modification can 
be  therapeutically  targeted,  resulting  in 
determined. Although it is tempting to 
consider this pathway a ubiquitous mech-
anism of suppression, it is likely that ex-
cess  MDSC  and  a  paucity  of  CD8
+  
T effector cells are one of multiple sup-
pressive  mechanisms  (Gajewski  et  al., 
2011; Schreiber et al., 2011). As Molon 
et al. (2011) point out, imaging studies 
using the same OVA-expressing EG.7 
thymoma tumor model have suggested 
that there is a barrier to deep tumor in-
filtration by TIL. However, we have re-
cently reported using intravital imaging 
that the same barrier did not exist in a 
different  tumor  model  (Schaer  et  al., 
2011). Specifically, during the early stages 
of the anti-B16 melanoma immune re-
sponse, gp100 self-antigen–specific Pmel-1   
CD8
+ TILs were found throughout the 
tumor (Schaer et al., 2011). Nonspecific, 
OVA-reactive OT-1 T cells also infil-
trated  the  tumor  to  the  same  degree 
without exhibiting tumor recognition, 
demonstrating that in the case of B16 
tumors,  activated T  cells  are  recruited   
regardless of antigen specificity. Further-
more, B16 tumors grow despite the fact 
that intratumoral Pmel-1 T cells recog-
nize cognate tumor antigens, similar to 
what has been described by prior imag-
ing studies of OVA-expressing thymomas 
(Mrass et al., 2006; Boissonnas et al., 2007; 
Schaer et al., 2011). These observations 
suggest ongoing intratumoral inhibition 
of the antitumor immune response. Pos-
sible suppressive mediators could be the 
same MDSCs that remain responsive 
to n-CCL2 and have been shown to in-
hibit intratumoral T cell function (Marigo   
et  al.,  2008;  Rodríguez  and  Ochoa, 
2008). T reg cells have also been known 
to play an important role in suppress-
ing tumor immunity, and in a manner 
somewhat synonymous with the data of 
Molon et al. (2011), tumors can prefer-
entially recruit T reg cells by secreting 
CCL22 (Nishikawa and Sakaguchi, 2010; 
Faget et al., 2011). In fact, in our own 
studies, we observed that T reg cell are 
in proximity to and interact with Pmel-1 
TIL (unpublished data). Thus, although it 
is clear in the models presented by Molon 
et al. (2011) that n-CCL2 represents a 
major barrier to tumor immunity, it is 
possible that not all tumor models use 
this same mechanism of immune evasion.
Figure 1.  Masking of chemokine signals through intratumoral production of RNS. Metabo-
lism of l-Arginine in the tumor by arginase and iNOS from myeloid or tumor cells leads to the gen-
eration of RNS, such as peroxynitrite, inside of the tumor microenvironment (left). This results in the 
nitrotyrosinylation of proteins, including the chemokine CCL2 (n-CCL2), in the tumor microenviron-
ment. Because n-CCL2 binds to its receptor (CCR2) with much lower affinity than the unmodified 
version, it prevents n-CCL2 from acting as a strong chemoattractant signal for antitumor T cells (top 
right). However, myeloid cells express higher levels of CCR2 receptor and are still able to migrate 
toward n-CCL2 gradients. When the small molecule inhibitor of RNS production AT38 is adminis-
tered, it blocks peroxynitrite formation and subsequent nitrotyrosinylation of CCL2. This restores 
deep T cell infiltration into the tumor, enhancing the effectiveness of both adoptive T cell therapy 
and endogenous antitumor responses (bottom right).1940 Tumor escape via chemokine nitrosylation | Schaer et al.
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